FDA Approves Mesoblast's Innovative Treatment for SR-aGVHD
The FDA has approved Mesoblast's treatment for children with steroid-refractory acute Graft Versus Host Disease, signaling hope for pediatric care.
The FDA has approved Mesoblast's treatment for children with steroid-refractory acute Graft Versus Host Disease, signaling hope for pediatric care.